On Dec. 8, 2015 Pfizer Inc. announced FDA accepted and granted Priority Review for a supplemental new drug application (sNDA) for Xalkori (crizotinib) for the treatment of patients with metastic non-small cell lung cancer (NSCLC) with ROS1-postive tumors. Priority Review status will accelerate FOriginal Article
You may also like
New alloys for manufacturing freeze-dryers
Navigating the Complexities of Emerging Therapy...
INTERPHEX 2025: Preventing Spills in the Manufacturing...
Agentic AI Growth Predicted, but More Than Half of...
Microsoft and SkyCell Collaborate on Pharma Supply...
Siemens Acquires Dotmatics, Extending AI Software...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.